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Abstract Bisphosphonates are antiresorptive drugs
commonly used to treat osteoporosis. It is not clear, how-
ever, what the inﬂuence of the time point of treatment is.
Recently developed in vivo micro-computed tomographic
(CT) scanners offer the possibility to study such effects on
bone microstructure in rats. The aim of this study was to
determine the inﬂuence of early and late zoledronic acid
treatment on bone in ovariectomized rats, using in vivo
micro-CT. Twenty-nine female Wistar rats were divided
into the following groups: ovariectomy (OVX, n = 5),
OVX and zoledronic acid (ZOL) at week 0 (n = 8), OVX
and ZOL at week 8 (n = 7), and sham (n = 9). CT scans
were made of the proximal tibia at weeks 0, 2, 4, 8, 12, and
16; and bone structural parameters were determined in the
metaphysis. Two ﬂuorescent labels were administered to
calculate dynamic histomorphometric parameters. At week
16, all groups were signiﬁcantly different from each other
in bone volume fraction (BV/TV), connectivity density,
and trabecular number (Tb.N), except for the early ZOL
and control groups which were not signiﬁcantly different
for any structural parameter. After ZOL treatment at week
8, BV/TV, structure model index, Tb.N, and trabecular
thickness signiﬁcantly improved in the late ZOL group.
The OVX and ZOL groups showed, respectively, higher
and lower bone formation rates than the control group.
Early ZOL treatment inhibited all bone microstructural
changes seen after OVX. Late ZOL treatment signiﬁcantly
improved bone microstructure, although the structure did
not recover to original levels. Early ZOL treatment resulted
in a signiﬁcantly better microstructure than late treatment.
However, late treatment was still signiﬁcantly better than
no treatment.
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Postmenopausal osteoporosis affects millions of women
worldwide and results in loss of bone mass and bone
microstructural changes, which lead to reduced bone
strength. It remains unknown how exactly the microstruc-
ture is affected over the time course of osteoporosis
development and to what extent this structure can be
recovered by drug treatment. Since the assessment of bone
structure in humans is still limited to a few peripheral sites,
the ovariectomized rat is used in many studies as an animal
model for osteoporosis in cross-sectional evaluations.
Numerous cross-sectional studies have determined the loss
of trabecular bone in the proximal tibia in rats following
ovariectomy (OVX) at different time points by measuring
bone structural parameters [1–3]. OVX has been shown to
decrease bone volume fraction, connectivity, and trabecu-
lar number and to increase trabecular separation and
structure model index, which indicates that trabecular bone
changes from plate-like to more rod-like in the proximal
tibial metaphysis of the female rat. However, conﬂicting
results were found for the effects of OVX on trabecular
thickness, showing increases, decreases, or no response at
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comparing averages per group only, which provides a
reduced sensitivity for detection of differences. In addition,
no information is obtained regarding the speciﬁc locations
of bone changes.
Recently, however, in vivo micro-computed tomo-
graphic (CT) scanners became available, which can
monitor the process of bone loss and microstructural
changes in small, living animals. So far, two studies have
been reported in which this equipment was used to monitor
changes in rat bones after OVX. Interestingly, these studies
reported, respectively, signiﬁcant increases [5] and
decreases [7] in trabecular thickness after OVX, indicating
that the response may vary. While the process of bone
degeneration after OVX is not fully understood, even less
information is available for the process of recovery after
drug treatment. The most widely used drugs for treatment
of diseases associated with increased bone resorption, such
as postmenopausal osteoporosis, are now bisphoshonates.
Many cross-sectional studies have determined the
effects of bisphosphonates in rats either as a preventive
treatment, before development of OVX-induced bone loss,
or as a recovering treatment after development of bone
loss. Although the results are difﬁcult to compare directly
due to differences in experimental design, preventive
treatment in animals may lead to the same amount of ﬁnal
bone mass as recovering treatment. The associated micro-
structure in terms of number and thickness of trabeculae,
however, can be different. While the inﬂuence of the time
point of treatment is highly relevant clinically, no studies
were found that directly compared the effects of a pre-
ventive and a recovering treatment on ﬁnal bone mass and
associated microstructure. In addition, the fact that only
results of cross-sectional studies have been reported com-
plicates comparison of the ﬁnal and original bone structure
and provides little or no information on the changes in
structure over time. Here also we expect that longitudinal
in vivo micro-CT imaging will potentially provide more
information about the speciﬁc changes in the bone, both
spatially and temporally.
For the present study, we had two goals: (1) to
determine the process of bone loss and bone microstruc-
tural changes in ovariectomized rats and (2) to determine
the effects of early and late treatment of osteoporotic rats
with a bisphosphonate. We used an in vivo high-resolu-
tion micro-CT scanner to image the proximal tibia of
female adult Wistar rats. For the treatment, zoledronic
acid (ZOL) was used, since this is a third-generation
bisphosphonate that proved a potent osteoclast inhibitor.
It has shown to be effective in cancer patients with bone
metastases and is currently being tested in clinical trials
as a promising therapeutic agent for osteoporotic patients
[8, 9].
Methods
Animals
Thirty-six female, 30-week-old, retired breeding Wistar
rats were obtained from Harlan Laboratories (Horst, The
Netherlands) and allowed to acclimate for 7 days before the
start of the experiment. The rats were maintained with a
cycle of 12 hours light and 12 hours darkness and allowed
to eat and drink ad libitum. The experiment was approved
by the Animals Ethics Committee of the University of
Maastricht, The Netherlands. The rats were divided into
four groups based on weight: control (n = 9), OVX
(n = 9), OVX and early ZOL (n = 9), OVX and late ZOL
(n = 9). All rats were ovariectomized at week 0, and the
control group underwent sham OVX. Success of OVX was
conﬁrmed at necropsy by determining atrophy of the
uterine horns. ZOL (kindly donated by Novartis Pharma-
ceutical, Basel, Switzerland) was dissolved in a saline
vehicle. The early ZOL group was administered ZOL at a
single dose of 20 lg/kg body weight s.c. at OVX (com-
parable to the phase III clinical trial dose used in
osteoporotic patients). The late ZOL group was adminis-
tered the same single dose 8 weeks after OVX. Eleven and
4 days before necropsy, the ﬂuorescent labels calcein
(Fluka, Buchs, Switzerland) and alizarin (Merck, Dietikon,
Switzerland) were administered s.c. in a saline vehicle to
all rats at doses of 30 mg/kg and 20 mg/kg body weight,
respectively, to evaluate bone formation dynamics in the
proximal tibial metaphysis. Rats were killed at 16 weeks
by exsanguination.
Micro-CT Scanning
Directly after the operation, a 6-mm micro-CT scan
(70 kV, 85 lA, 1,000 projections per 180 degrees, 350 ms
integration time) with an isotropic resolution of 15 lm was
made of the proximal tibia using an in vivo micro-CT
scanner (vivaCT 40; Scanco Medical, Bruettisellen, Swit-
zerland). The CT scanner was calibrated, and a beam-
hardening correction algorithm was applied to all scans.
Follow-up in vivo CT scans were made after 2, 4, 8, 12,
and 16 weeks to monitor bone structure. One CT scan took
35 minutes, during which the animal was anesthetized with
isoﬂurane and the scanned leg was placed in a custom-
made leg-ﬁxating device. The design of the rat holder was
such that the left leg was not exposed to radiation while
scanning the right leg. Radiation damage to the scanned
bone was not expected to occur, based on a previous study
in which 8-weekly CT scans with the same radiation dose
caused no detected bone damage [10]. In that study, we
also showed that the reproducibility of all structural
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about 1%.
Image processing included gaussian ﬁltering and seg-
mentation and was described elsewhere in detail [10]. In
brief, the same ﬁltering and segmentation values were used
for every measurement of each animal (sigma = 0.7, sup-
port = 1, threshold density = 0.504 g hydroxyapatite/cc,
equivalentto22%ofmaximalgray-scalevalue).Fromevery
baseline and follow-up CT scan, the metaphyseal trabecular
bone was manually selected and bone structural parameters
(bone volume fraction [BV/TV], connectivity density
[Conn.D], structure model index [SMI], trabecular number
[Tb.N], trabecular thickness [Tb.Th], and trabecular sepa-
ration [Tb.Sp]) were automatically determined. The average
attenuation coefﬁcient of the trabecular bone tissue was
determined for all measurements using a protocol provided
by the manufacturer of the micro-CT scanner. With this
protocol, the gray levels of voxels near the trabecular sur-
faces are not included, to ensure that the measurements are
not affected by partial volume effects. Also, cortical thick-
ness of the metaphysis was analyzed. The cortical bone
startingfromthetibia–ﬁbulajunctionwasmanuallyselected
for each measurement, resulting in a region approximately
1.8 mm long. The same ﬁltering and segmentation values
were used as for the trabecular analysis. Cortical thickness
was automatically determined from the selected region.
When two CT scans of the same animal are made at
different time points, the position of the animal in the
scanner will not be exactly the same and, therefore, the CT
scans will also differ. In order to detect bone structural
changes on a micro level, one CT scan needs to be trans-
lated and rotated to match the other. We developed image
registration software that registers two scans based on
minimizing the correlation coefﬁcient [11]. Every follow-
up scan is registered with the ﬁrst scan, thereby revealing
any possible changes in the microstructure and minimizing
errors in the region of interest for the structural parameters.
Mechanical Testing
After sacriﬁce, all left tibiae were dissected and used for
two different mechanical tests. First, a standard three-point
bending test was applied. The tibiae were placed on the
lateral surface on two rounded supporting bars with a
distance of 2.4 mm. A preload of 1 N was applied (Z020;
Zwick, Ulm, Germany) at the medial surface of the
diaphysis by lowering a third rounded bar. A constant
displacement rate of 6 mm/minute was applied until fail-
ure. Displacement was measured from the actuator
displacement transducer of the testing machine. Stiffness,
ultimate force, and ultimate displacement were calculated
for each sample.
To assess the mechanical properties of the proximal
tibia, a proximal tibia compression test was performed
similar to the method of Hogan et al. [12]. A 4-mm slice of
the proximal metaphysis including both cortical and tra-
becular bone was sawed below the growth plate using a
diamond saw (Accutom-5; Struers, Ballerup, Denmark).
This slice was axially compressed (Z020) during ﬁve pre-
conditioning cycles between 1 and 70 N. After the last
preconditioning cycle, axial compressive load was applied
at 0.5 mm/minute until failure, while axial displacement
was measured using an extensometer. Stiffness, ultimate
force, and ultimate displacement were determined for all
samples.
Histomorphometry
At necropsy, all right tibiae were ﬁxed in 70% ethanol and
embedded in methylmethacrylate (Technovit 9100; Heraeus
Kulzer, Wehrheim, Germany). Thin sections (5 lm) were
cut to determine ﬂuorochrome-based dynamic histomor-
phometric parameters of bone formation using an Axiophot
photomicroscope (Zeiss, Oberkochen, Germany) linked to a
camera (CF 15/4 MC; Kappa, Gleichen, Germany), and a
QUANTIMET 600 image analysis system was used to cal-
culate the amount of mineralized surface per bone surface
(MS/BS, percentage), corrected mineral apposition rate
(MAR) (lm/day), and bone formation rate (BFR) per bone
surface (lm/day). Calculations of the dynamic parameters
were performed as recommended previously [13].
Statistics
Since this experiment concerned repeated measures in
multiple groups, several statistical tests were performed to
reveal changes in parameter values over time and between
groups. For all structural parameters, the percentage
change at different time intervals was calculated for each
animal individually. A one-way analyses of variance
(ANOVA) with repeated measures was performed on the
percentage change for all structural parameters and all
groups. Furthermore, a one-way ANOVA with a Bonfer-
roni post-hoc test was used to determine differences
between the groups at all time points for each structural
parameter. Also, a one-way ANOVA with a Bonferroni
post-hoc test was used to determine differences between
the groups in cortical thickness, histomorphometric results,
and mechanical results. For each group, a paired Student’s
t-test was performed on the absolute values of the structural
parameters of each time point compared to baseline values,
to determine the earliest point at which a detectable change
was found. A paired Student’s t-test was used to determine
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paired Student’s t-test was performed on the absolute val-
ues between each measurement for each group and
structural parameter. P\0.05 was considered signiﬁcant.
Results
Ovariectomy
Based on the uterine weight, we determined seven
unsuccessful OVXs. The rats concerned were removed
from further analyses, which left nine rats in the control
group, ﬁve in the OVX group, seven in the OVX and
late ZOL group, and eight in the OVX and early ZOL
group. For each animal, we determined the percentage
change in structural parameters compared to the values
at week 0. Figure 1 shows the average percentage
change and upper standard deviation for all groups for
BV/TV, Conn.D, SMI, Tb.N, Tb.Th, and Tb.Sp. The
OVX group without treatment showed large changes in
structural parameters, indicating the development of
OVX-induced bone loss (Figs. 1 and 2). Paired Student’s
t-test indicated signiﬁcant changes within 2 weeks after
OVX for all structural parameters. BV/TV, Conn.D, and
Tb.N decreased during the experiment and SMI and
Tb.Sp increased. Both Tb.Th and Tb.N decreased within
2 weeks, indicating that both thinning and complete
resorption of trabeculae started directly after OVX. The
initial rapid loss of bone and connectivity was largely
accompanied by trabecular thinning, while secondary,
slower loss of bone was concomitant with a decrease in
Tb.N. While BV/TV, Conn.D, SMI, Tb.N, and Tb.Sp
showed continuous changes in the same direction
throughout the experiment, Tb.Th initially decreased
signiﬁcantly until 4 weeks after OVX and then increased
again until after 16 weeks Tb.Th was signiﬁcantly higher
than in the control group.
Fig. 1 Average percentage
change in structural parameters
in the metaphyseal proximal
tibia and upper standard
deviation for all groups at all
time points. Brackets indicate
P\0.05 at week 16
J. E. M. Brouwers et al.: Bisphosphonate Treatment Assessed by In Vivo Micro-CT 205
123The absolute average values and standard deviations
for all structural parameters of all measurements are
shown in Table 1. At the starting point, some differences
in the values between the groups were present. This was
due to the fact that some animals, which mostly had a
relatively low BV/TV, were removed from the study
because they did not respond to the OVX. However, since
we compared the relative changes in each animal, the
results were most likely not affected by the difference in
absolute values.
ZOL Treatment
The early ZOL treatment and control groups were not
signiﬁcantly different at all time points for all structural
parameters.
Up until 8 weeks after OVX, when ZOL was adminis-
tered to rats in the late treatment group, the OVX group and
the late treatment group were not signiﬁcantly different for
all structural parameters. BV/TV, SMI, Tb.Th, and Tb.N
were signiﬁcantly improved in the late ZOL group 4 weeks
after the single ZOL injection (Table 2). In addition, Tb.Sp
signiﬁcantly improved within 8 weeks after injection,
while Conn.D showed no signiﬁcant response. Between
weeks 12 and 16, all structural parameters stayed constant.
At week 16, BV/TV, Conn.D, and Tb.N were signiﬁ-
cantly different between all groups except for the early
treatment and control groups (Table 3). Tb.Th was only
signiﬁcantly different between the control and OVX
groups. Although substantial differences in Tb.Sp and SMI
were seen between all groups, except for the early treat-
ment and control groups, signiﬁcant differences were only
found between the OVX and control groups and between
the OVX and early treatment groups.
Fig. 2 Same slice of an unprocessed CT scan of the same rat in the OVX group taken at weeks 0 (a), 2 (b), 4 (c), 8 (d), 12 (e), and 16 (f). Images
show typical trabecular bone loss due to OVX in the metaphysis. Green line shows the analyzed metaphyseal bone
Table 1 Mean values and standard deviation of all structural parameters of all groups at the start of the experiment
Group BV/TV (1) Conn.D (1/mm) SMI (1) Tb.N (1/mm) Tb.Th (lm) Tb.Sp (lm)
Control 0.17 (0.056) 41 (47) 1.52 (0.53) 1.89 (1.38) 105 (49) 613 (368)
OVX 0.26 (0.055) 141 (76) 1.22 (0.39) 3.77 (1.66) 84 (10) 335 (174)
OVX + late ZOL 0.23 (0.062) 86 (66) 1.23 (0.34) 2.77 (1.55) 89 (13) 482 (227)
OVX + early ZOL 0.17 (0.056) 38 (21) 1.70 (0.39) 1.86 (0.80) 95 (7) 647 (207)
Table 2 P values of paired Student’s t-test in the late ZOL group
after ZOL treatment
Structural parameter P for weeks 8–12 P for weeks 8–16
BV/TV 0.001
* 0.004
*
Conn.D 0.249 0.181
SMI 0.003
* 0.004
*
Tb.N 0.041
* 0.005
*
Tb.Th 0.000
* 0.000
*
Tb.Sp 0.344 0.008
*
* Signiﬁcant (P\0.05)
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change over time and did not differ between groups at all
time points.
Aging
An ANOVA with repeated measures on all structural
parameters of the control group was performed to deter-
mine if there was a signiﬁcant effect of aging. BV/TV
and Tb.N were found to signiﬁcantly decrease and Tb.Sp
was found to signiﬁcantly increase due to aging. All other
structural parameters did not change signiﬁcantly in
16 weeks.
An ANOVA with repeated measures was performed on
the percentage change in structural parameters comparing
the control and early treatment groups to determine any
signiﬁcant differences. BV/TV and Tb.N showed a sig-
niﬁcant effect of age, treatment, and age * treatment and
Tb.Sp showed a signiﬁcant effect of age and age * treat-
ment. While BV/TV decreased signiﬁcantly over time in
both the early treatment and control groups, it was found to
decrease at a higher rate in the latter. Tb.N signiﬁcantly
decreased over time in the control group; however, it did
not signiﬁcantly change in the early treatment group as a
net result of OVX, aging, and ZOL treatment. Tb.Sp sig-
niﬁcantly increased in the control group due to aging, while
it did not in the early treatment group.
Cortical Thickness
OVX initially led to a decrease in metaphyseal cortical
thickness, and at 4 weeks both the OVX and the late ZOL
groups were signiﬁcantly lower than the early ZOL group
(Fig. 3). However, after 4 weeks it increased again in the
OVX group, and at 16 weeks cortical thickness was sig-
niﬁcantly higher than in the control group. Early ZOL
treatment inhibited the changes in cortical thickness. The
late ZOL group, just like the OVX group, showed an
increase in cortical thickness between 4 and 16 weeks,
although this was less pronounced.
Mechanical Testing
Experimental test results were obtained for seven (control),
ﬁve (OVX), six (OVX and late ZOL), and seven (OVX and
early ZOL) tibiae. No signiﬁcant differences were found
between all parameters determined in the three-point
bending test (Fig. 4a).
For the results from the proximal tibia compression test,
a signiﬁcant difference in ultimate displacement was found
between the OVX group and the early ZOL group and
between the OVX and the control groups (Fig. 4b).
Although not signiﬁcantly determined, a trend was
observed in which OVX resulted in a lower stiffness and
ultimate force, while late ZOL treatment partially
Table 3 P values of ANOVA plus Bonferroni post-hoc test comparing all groups at all time points for all structural parameters
Group DBV/TV DConn.D DSMI
2481 2 1 6 2481 2 1 6 2481 2 1 6
1 vs. 2 0.010
* 0.000
* 0.000
* 0.000
* 0.000
* 0.025
* 0.001
* 0.000
* 0.000
* 0.000
* 0.027
* 0.008
* 0.004
* 0.001
* 0.003
*
1 vs. 3 0.005
* 0.000
* 0.000
* 0.000
* 0.000
* 0.341 0.021
* 0.001
* 0.000
* 0.005
* 0.929 0.473 0.141 0.305 0.24
1 vs. 4 0.999 0.999 0.999 0.999 0.322 0.999 0.999 0.999 0.999 0.999 0.999 0.999 0.999 0.999 0.999
2 vs. 3 0.999 0.999 0.579 0.000
* 0.000
* 0.999 0.906 0.811 0.042
* 0.027
* 0.598 0.443 0.667 0.148 0.37
2 vs. 4 0.000
* 0.000
* 0.000
* 0.000
* 0.000
* 0.079 0.001
* 0.000
* 0.000
* 0.000
* 0.011
* 0.005
* 0.003
* 0.001
* 0.003
*
3 vs. 4 0.000
* 0.000
* 0.000
* 0.000
* 0.000
* 0.9 0.023
* 0.001
* 0.000
* 0.000
* 0.421 0.29 0.104 0.331 0.206
Group DTb.N DTb.Th DTb.Sp
2 481 2 1 6 248 1 2 1 6 2 481 2 1 6
1 vs. 2 0.088 0.001
* 0.000
* 0.000
* 0.000
* 0.003
* 0.002
* 0.673 0.999 0.013
* 0.21 0.006
* 0.001
* 0.000
* 0.000
*
1 vs. 3 0.108 0.019
* 0.005
* 0.007
* 0.018
* 0.008
* 0.002
* 0.325 0.999 0.999 0.099 0.072 0.2 0.802 0.999
1 vs. 4 0.999 0.999 0.999 0.999 0.999 0.999 0.999 0.999 0.999 0.999 0.999 0.999 0.999 0.999 0.999
2 vs. 3 0.999 0.999 0.353 0.001
* 0.000
* 0.999 0.999 0.999 0.999 0.152 0.999 0.999 0.128 0.001
* 0.000
*
2 vs. 4 0.45 0.001
* 0.000
* 0.000
* 0.000
* 0.001
* 0.001
* 0.265 0.999 0.06
* 0.492 0.007
* 0.001
* 0.000
* 0.000
*
3 vs. 4 0.623 0.027
* 0.004
* 0.003
* 0.002
* 0.003
* 0.001
* 0.109 0.999 0.999 0.279 0.084 0.187 0.667 0.999
Groups: 1, control; 2, OVX; 3, late ZOL; 4, early ZOL
* Signiﬁcant (P\0.05)
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larger extent.
Histomorphometry
Histomorphometric results were obtained for ﬁve (control),
ﬁve (OVX), six (OVX and late ZOL), and ﬁve (OVX and
early ZOL) rats. The OVX group showed a signiﬁcantly
higher mineralizing surface (MS/BS) and BFR and a sub-
stantially higher mineral apposition rate (MAR) than the
control group (Fig. 5). Both ZOL groups showed a sig-
niﬁcantly lower MS/BS and BFR than the OVX group and
control group, while MAR was signiﬁcantly lower than
only the OVX group. Additionally, the late ZOL group had
a signiﬁcantly lower MS/BS and a nonsigniﬁcantly lower
BFR than the early ZOL group.
Discussion
In this study we assessed the effects of OVX and of early
and late ZOL treatments after OVX on the microstructure
of metaphyseal bone in the proximal tibia of aged, female
Wistar rats over a 16-week time course, using in vivo high-
resolution micro-CT.
OVX induced signiﬁcant changes in all structural
parameters within 2 weeks, indicating the rapid develop-
ment of OVX-induced bone loss. An initial phase of rapid
decreases in BV/TV and Conn.D was seen, followed by a
secondphaseinwhichchangestookplaceatlowerrates.The
initialrapidlossofboneandconnectivitywaslargelycaused
by trabecular thinning, while the secondary, slower loss of
bonewasaccompaniedbyadecrease inTb.N.OVXinduced
large decreases in BV/TV, Conn.D, and Tb.N and large
increases in Tb.Sp and SMI, indicating the change of more
plate-torod-likebone,whichagreeswiththeliteratureonthe
effects of OVX in rat tibiae [2, 14–16]. A different response
was, however, seen in Tb.Th, which initially decreased until
4 weeks after OVX and then increased until at the end point
of the experiment it was higher than in the control group. A
possible explanation for this response could be that, due to
increased osteoclast activity, initially most trabeculae will
become thinner, while only few are completely resorbed.
After a certain period of resorption, the thinner trabeculae
willbeperforatedandcompletelyresorbed.Sincethethicker
trabeculae remain present, the average Tb.Th will increase.
Another possible explanation would be that mechanical
adaptation takes place. Since much bone is lost after OVX
Fig. 4 Stiffness, ultimate force,
and ultimate displacement
determined from three-point
bending tests on diaphyseal tibia
(a) and axial compression tests
(b) on metaphyseal bone.
Groups: 1, control; 2, OVX; 3,
late ZOL; 4, early ZOL.
*Signiﬁcant difference between
groups based on ANOVA and
Bonferroni post-hoc test
(P\0.05)
Fig. 3 Average percentage change in cortical thickness in the
metaphyseal proximal tibia and upper standard deviation for all
groups at all time points. At week 4 the OVX and the late ZOL groups
were signiﬁcantly lower than the early ZOL group, and at week 16 the
OVX group was signiﬁcantly higher than the control group
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bearing goes through the remaining trabeculae. Therefore,
the stress increases in these trabeculae, which stimulates
bone formation and would lead to increased Tb.Th. It is also
possible that a combination of these mechanisms actually
takes place. In the two studies published to date regarding
in vivo micro-CT monitoring of the effects of OVX on the
metaphysealproximaltibiainrats,thelossoftrabecularbone
was similar to what was seen here [5, 7]. However, Tb.Th
signiﬁcantly increased in one study and decreased in the
other directly after OVX. Although the same rat strain was
used and the same anatomical location was studied, it could
be that differences, such as the use of retired breeders vs.
virgin rats, age, or type of data analysis, led to variable
results.
Early ZOL injection at the time of OVX completely pre-
vented all changes in structural parameters and, thus, the
development of OVX-induced bone loss. Aging caused a
signiﬁcant decrease in BV/TV, Conn.D, and Tb.N and an
increaseinTb.Spinthecontrolgroup,which agreeswith the
literature [7]. However, a signiﬁcant decrease was merely
seen in BV/TV in the early ZOL group and at a signiﬁcantly
lower rate than in the control group. This indicates that a
single injectionofZOLwaspowerfulenoughtoinhibiteven
natural deteriorationof bone volume and microstructuredue
to aging. One year of weekly ZOL injections of a concen-
trationaslowas0.3 lg/kgcompletelysuppressedtheeffects
of OVX in vertebrae of Sprague-Dawley rats, and 1.5 lg/kg
was needed to retain all structural parameters and mechan-
ical properties in the femurs [8, 17]. Similarly, 69 weeks of
weekly ZOL injections in OVX rhesus monkeys reduced
bone loss in a dose-dependent manner [18]. In a phase II
study, both a yearly and a quarterly ZOL dose increased
spinal and femoral bone mineral density in postmenopausal
women [19]. In the current study, we have shown the long-
term, potent inhibiting effects of ZOL on both BV/TV and
the microstructure in rats.
WhilethepreventiveeffectsofZOLhavepreviouslybeen
studied in rats [8, 17], the effect of ZOL treatment after the
development of OVX-induced bone loss on the
microstructure, which more closely resembles the clinical
situation, is new. Late ZOL injection after 8 weeks of bone
loss development inhibited further bone loss. Possibly as a
result of the ﬁlling of resorption cavities [20], a temporary
but signiﬁcant increase in BV/TV and thickness and a sig-
niﬁcant decrease in SMI were seen directly after ZOL
administration. Four weeks later, however, all structural
parametersstayedconstant.ThisisincontrastwiththeOVX
group, which still showed deterioration of bone structure
after 8 weeks. Overall, bisphosphonate treatment after the
onset of osteoporosis is known to stabilize or increase BV/
TV and Tb.Th in both humans and other animals, which
agrees with the data presented here [21–23]. It is generally
thought that the underlying mechanism for an increase in
BV/TVandTb.Thistheinhibitingeffectofbisphosphonates
on bone resorption preventing further thinning of trabeculae
andthereductionofremodelingspacebyﬁllingofresorption
cavities, leading to increased bone mass [20, 24].
Cortical thickness ﬁrst decreased as a result of OVX,
later increased again, and ﬁnally was higher than that of the
control group. Both increases and decreases in metaphyseal
tibial cortical thickness have been reported in cross-sec-
tional studies, which may be due to different analytic
methods or different time points of sacriﬁce [25, 26]. Early
ZOL treatment resulted in a similar cortical thickness as
seen in the control groups, which was fairly constant. Late
ZOL treatment resulted in a similar pattern as in the OVX
group, although less pronounced, which may be explained
by the inhibiting effect of ZOL on bone remodeling rate.
Cortical thickness proﬁles in all groups were similar to
those for Tb.Th, which may be interpreted as an indication
that mechanical adaptation takes place in both cortical and
trabecular bone after sustained bone loss.
No signiﬁcant differences were found in mechanical
properties determined in the three-point bending test
between the OVX and control groups, which agrees with
the literature [27, 28]. Also, no signiﬁcant inﬂuence of
ZOL treatment was found on the mechanical properties
determined in the three-point bending test, which may be
expected as ZOL inhibits bone resorption and does not
Fig. 5 Dynamic bone histomorphometric parameters for all groups in
the metaphyseal proximal tibia. Groups: 1, control; 2, OVX; 3, late
ZOL; 4, early ZOL. Based on ANOVA and a Bonferroni test,
asigniﬁcantly different from group 1,
bsigniﬁcantly different from
group 2,
csigniﬁcantly different from group 3, and
dsigniﬁcantly
different from group 4 (P\0.05)
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123increase formation. In the proximal tibia compression test,
ultimate displacement was found to be higher in the OVX
group than in the other groups. ZOL treatment partially
recovered this increase in ultimate displacement. Although
not signiﬁcantly, ultimate force and stiffness tended to be
lower in the OVX group, while ZOL treatment inhibited
this. The low number of animals per group and variability
in the data unfortunately limit the interpretation of these
results. It is known that while endosteal bone resorption
takes place during aging and is increased as a result of
OVX, periosteal apposition increases as well [29–34],
which was also seen in our CT scans (data not shown),
thereby compensating for the loss of endocortical and tra-
becular bone [35]. Therefore, loss of trabecular and
endocortical bone may not necessarily mean loss of
strength. While ﬁrst-generation bisphosphonates, such as
etidronate, have been shown to directly decrease mineral-
ization of bone [9, 36], it is thought that ZOL may increase
mineralization by inhibiting resorption and thereby allow-
ing longer mineralization [37, 38]. Furthermore,
microdamage could accumulate, and both of these effects
could alter the mechanical properties of the bone tissue.
Nonetheless, the trends in the mechanical properties
resembled the trends in BV/TV and showed that ZOL
inhibited the changes resulting from OVX.
Bone-forming activity was slightly higher in the OVX
compared to the control group, reﬂecting an increased
turnover rate. Both ZOL groups displayed lower bone-
forming parameters compared to the control and OVX
groups, probably due to suppression of bone formation and
resorption. Additionally, the late ZOL group tended to
show slightly less bone-forming activity than the early
ZOL group, possibly due to the later time point of treat-
ment. These results agree with previous reports of
decreased osteoblast and osteoclast numbers after ZOL
injection and decreased number of resorption lacunae [20,
39]. CT-derived estimates of mineralization of metaphyseal
trabecular bone were, however, not signiﬁcantly increased
in ZOL-treated rats. This would indicate that ZOL treat-
ment did not inﬂuence mineralization in this time frame.
Aspreviouslymentioned,attimes,substantialdifferences
were found between groups; however, due to a relatively
high standard deviation, no signiﬁcant differences unfortu-
nately were detected. This high standard deviation was
mostly seen in the OVX and late treatment group. This was
mostlikelycausedbythefactthatretiredbreederswereused,
whichareknowntoshowavariableresponsetoOVX.Dueto
anunsuccessfulOVX,sevenanimalswereremovedfromthe
study.Thisdecreasedthenumberofanimals usedinthe data
analysis and, since these were mostly animals with a rela-
tively low BV/TV, the average BV/TV at the start of the
study was higher in the OVX and late treatment groups.
Therefore, we performed statistical tests on percentage
changes in structural parameters rather than on the absolute
values. The trend for the percentage and absolute changes
looked similar and the P values were similar for most cases.
However, when ANOVA was performed on the absolute
values comparing all groups at week 16, less signiﬁcant
differences in structural parameters were found, indicating
the more sensitive approach of the in vivo experimental
design.
Another limitation to this study was the fact that on
average, at 8 weeks in the study, the OVX group was in a
more deteriorated condition than the late treatment group,
while there was no demonstrable explanation for this.
Although the ANOVA showed no signiﬁcant differences
between the groups, the treatment group still had a more
favorable starting point when ZOL was administered.
However, because after ZOL injection signiﬁcant improve-
ment took place while the OVX group still deteriorated, it is
shown that this will not have affected the ﬁnal conclusions.
The method of in vivo CT scans combined with image
registration software presented here has enabled us to study
our goals in a more efﬁcient way in terms of number of
animals needed in the experiment. Follow-up micro-CT
scans were made of the same animals, enabling us to use
paired statistics and relative percentage changes in struc-
tural parameters. By registering all CT scans, we were able
to select the same part of the metaphyseal trabecular bone
for every measurement, thereby decreasing the variation in
structural parameters due to a varying selected region of
interest.
In conclusion, OVX induced rapid changes in trabecular
bone mass and structure. A single injection of ZOL at OVX
completely inhibited these changes in bone mass and
structure seen in osteoporotic rats. A single ZOL injection
after OVX-induced bone loss improved bone mass and
structure, per group and compared to the control group.
BV/TV and the associated bone microstructure at the end
point of this study were, however, signiﬁcantly less
favorable than in the early treatment group.
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